SCHEMBL1723443

SCHEMBL1723443

Nc1cc(O)[nH]c(=O)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309011 0.76
SCHEMBL10017208 0.73
SCHEMBL1934832 0.73
SCHEMBL6515509 0.73
SCHEMBL1765938 0.73
SCHEMBL17112672 0.73
SCHEMBL1762277 0.72 TSHR (0.52)
Hydrochloric Acid SCHEMBL9534244 0.71 TSHR (0.50)
SCHEMBL32688411 0.68 HPGD (0.41)
SCHEMBL313299 0.68 TSHR (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188254-B2 C-class oligonucleotide analogs with enhanced immunostimulatory potency COLEY PHARMACEUTICAL GMBH (DE) 2012-05-29 US claimed
EP-1728863-A2 C-class oligonucleotide analogs with enhanced immunostimulatory potency Coley Pharmaceutical GmbH (DE) 2006-12-06 EP claimed
EP-1678303-A2 C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY Coley Pharmaceutical GmbH (DE) 2006-07-12 EP claimed
US-20050239734-A1 C-class oligonucleotide analogs with enhanced immunostimulatory potency COLEY PHARMACEUTICAL GMBH (DE) 2005-10-27 US claimed
WO-2005042018-A2 C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY COLEY PHARMACEUTICAL GMBH (DE) 2005-05-12 WO claimed
EP-1991678-B2 COMPOSITIONS AND METHODS FOR OLIGONUCLEOTIDE FORMULATIONS RECHTSANWALT THOMAS BECK (DE) 2020-07-15 EP disclosed
US-20180171338-A1 COMPOSITIONS AND METHODS FOR OLIGONUCLEOTIDE FORMULATIONS ADIU TIDE PHARMACEUTICALS GMBH (DE) 2018-06-21 US disclosed
EP-1991678-B1 COMPOSITIONS AND METHODS FOR OLIGONUCLEOTIDE FORMULATIONS ADIUTIDE PHARMACEUTICALS GMBH (DE) 2015-09-09 EP disclosed
EP-2405002-B1 Compositions and methods for oligonucleotide formulations ADIUTIDE PHARMACEUTICALS GMBH (DE) 2014-09-24 EP disclosed
US-8188254-B2 C-class oligonucleotide analogs with enhanced immunostimulatory potency COLEY PHARMACEUTICAL GMBH (DE) 2012-05-29 US disclosed
EP-2405002-A1 Compositions and methods for oligonucleotide formulations AdiuTide Pharmaceuticals GmbH (DE) 2012-01-11 EP disclosed
US-20080045473-A1 Compositions and methods for oligonucleotide formulations COLEY PHARMACEUTICAL GMBH (DE) 2008-02-21 US disclosed
WO-2007095316-A2 COMPOSITIONS AND METHODS FOR OLIGONUCLEOTIDE FORMULATIONS COLEY PHARMACEUTICAL GMBH (DE) 2007-08-23 WO disclosed
EP-1728863-A2 C-class oligonucleotide analogs with enhanced immunostimulatory potency Coley Pharmaceutical GmbH (DE) 2006-12-06 EP disclosed
EP-1678303-A2 C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY Coley Pharmaceutical GmbH (DE) 2006-07-12 EP disclosed
US-20050239734-A1 C-class oligonucleotide analogs with enhanced immunostimulatory potency COLEY PHARMACEUTICAL GMBH (DE) 2005-10-27 US disclosed
WO-2005042018-A2 C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY COLEY PHARMACEUTICAL GMBH (DE) 2005-05-12 WO disclosed